

Jacek Kubica

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1557306/publications.pdf>

Version: 2024-02-01

242
papers

12,907
citations

94381

37
h-index

24961

109
g-index

280
all docs

280
docs citations

280
times ranked

12996
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and Efficacy of Different Antithrombotic Strategies after Transcatheter Aortic Valve Implantation: A Network Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2022, 122, 216-225.	1.8	4
2	Oral NAloxone to overcome the moRphine effect in acute COronary syndrome patients treated with TICagrelor â€” NARCOTIC trial. <i>Cardiology Journal</i> , 2022, 29, 432-440.	0.5	6
3	Repetitive use of LEvosimendan in Ambulatory Heart Failure patients (LEIA-HF) - The rationale and study design. <i>Advances in Medical Sciences</i> , 2022, 67, 18-22.	0.9	7
4	IMPACT of PCSK9 inhibition on clinical outcome in patients during the inflammatory stage of the SARS-COV-2 infection: Rationale and protocol of the IMPACT-SIRIO 5 study. <i>Cardiology Journal</i> , 2022, 29, 140-147.	0.5	9
5	Impact of COVIDâ€™19 pandemic on acute heart failure admissions and mortality: a multicentre study (COVâ€™HFâ€™SIRIO 6 study). <i>ESC Heart Failure</i> , 2022, 9, 721-728.	1.4	20
6	Diurnal Variability of Platelet Aggregation in Patients with Myocardial Infarction Treated with Prasugrel and Ticagrelor. <i>Journal of Clinical Medicine</i> , 2022, 11, 1124.	1.0	3
7	Management and predictors of clinical events in 75 686 patients with acute myocardial infarction. <i>Kardiologia Polska</i> , 2022, 80, 468-475.	0.3	8
8	The impact of mild therapeutic hypothermia on platelet reactivity in comatose survivors of cardiac arrest with acute myocardial infarction treated with ticagrelor. <i>Cardiology Journal</i> , 2022, , .	0.5	3
9	Efficacy and safety of intracoronary epinephrine versus conventional treatments alone in STEMI patients with refractory coronary noâ€™reflow during primary PCI: The RESTORE observational study. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 602-611.	0.7	20
10	Endogenous fibrinolysisâ€™ Relevance to clinical thrombosis risk assessment. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13471.	1.7	7
11	Pharmacodynamic and clinical efficacy of reduced ticagrelor maintenance doses in patients with coronary artery disease. <i>Current Medical Research and Opinion</i> , 2021, 37, 195-206.	0.9	2
12	Antiplatelets in acute coronary syndrome in Poland â€™ from guidelines to clinical practice. <i>Postepy W Kardiologii Interwencyjnej</i> , 2021, 17, 141-154.	0.1	2
13	Characteristics of patients from the Polish Registry of Acute Coronary Syndromes during the COVID-19 pandemic: the first report. <i>Kardiologia Polska</i> , 2021, 79, 192-195.	0.3	6
14	Low dose of ROSuvastatin in combination with EZEtimibe effectively and permanently reduce low density lipoprotein cholesterol concentration independently of timing of administration (ROSEZE): A randomized, crossover study â€™ preliminary results. <i>Cardiology Journal</i> , 2021, 28, 58-66.	0.5	2
15	ANalgesic Efficacy and safety of MORphiNe versus methoxyflurane in patients with acute myocardial infarction: the rationale and design of the ANEMON-SIRIO 3 study: a multicentre, open-label, phase II, randomised clinical trial. <i>BMJ Open</i> , 2021, 11, e043330.	0.8	4
16	C-Reactive Protein as a Risk Marker for Post-Infarct Heart Failure over a Multi-Year Period. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3169.	1.8	17
17	Ticagrelor vs Clopidogrel for Patients With Acute Coronary Syndrome Undergoing Percutaneous Intervention. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 890.	3.8	0
18	COVID-19 pandemic year in the cardiology department. <i>Medical Research Journal</i> , 2021, 6, 40-46.	0.1	1

#	ARTICLE	IF	CITATIONS
19	Five-Year Comparative Efficacy of Everolimus-Eluting vs. Resolute Zotarolimus-Eluting Stents in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. <i>Journal of Clinical Medicine</i> , 2021, 10, 1278.	1.0	1
20	Mild therapeutic hypothermia after out-of-hospital cardiac arrest: What does really matter?. <i>Cardiology Journal</i> , 2021, 28, 293-301.	0.5	5
21	Evidence-Based Aerobic Exercise Training in Metabolic-Associated Fatty Liver Disease: Systematic Review with Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 1659.	1.0	12
22	Glasgow Coma Scale score of more than four on admission predicts in-hospital survival in patients after out-of-hospital cardiac arrest. <i>American Journal of Emergency Medicine</i> , 2021, 42, 90-94.	0.7	6
23	Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2021, 42, 4638-4651.	1.0	80
24	Diagnostic Performance of Selected Baseline Electrocardiographic Parameters for Prediction of Left Ventricular Remodeling in Patients with ST-Segment Elevation Myocardial Infarction. <i>Journal of Clinical Medicine</i> , 2021, 10, 2405.	1.0	4
25	Cost-effectiveness of levosimendan in patients with exacerbation of chronic heart failure – a single-center perspective. <i>Medical Research Journal</i> , 2021, 6, 114-118.	0.1	0
26	Pharmacokinetic Modeling of Morphine's Effect on Plasma Concentrations of Ticagrelor and Its Metabolite in Healthy Volunteers. <i>Frontiers in Physiology</i> , 2021, 12, 663170.	1.3	5
27	Out-of-hospital cardiac arrest and COVID-19 pandemic. <i>Medical Research Journal</i> , 2021, 6, 83-85.	0.1	0
28	Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTEMI-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy. <i>European Heart Journal</i> , 2021, 42, 2973-2985.	1.0	21
29	Development and Validation of a Practical Model to Identify Patients at Risk of Bleeding After TAVR. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1196-1206.	1.1	24
30	A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo-controlled, investigator-initiated, multicenter clinical study. <i>Cardiology Journal</i> , 2021, 28, 607-614.	0.5	3
31	Long-term outcome of rotational atherectomy according to burr-to-artery ratio and changes in coronary artery blood flow: Observational analysis. <i>Cardiology Journal</i> , 2021, , .	0.5	3
32	Elevated serum transaminases in patients with acute coronary syndromes: Do we need a revision of exclusion criteria for clinical trials?. <i>Cardiology Journal</i> , 2021, , .	0.5	6
33	Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. <i>Journal of the American College of Cardiology</i> , 2021, 78, 421-433.	1.2	58
34	Long-Term Outcomes Following Drug-Eluting Balloons Versus Thin-Strut Drug-Eluting Stents for Treatment of In-Stent Restenosis (DEB-DRAGON-Registry). <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010868.	1.4	9
35	Effects of SGLT2 Inhibitors on Ion Homeostasis and Oxidative Stress associated Mechanisms in Heart Failure. <i>Biomedicine and Pharmacotherapy</i> , 2021, 143, 112169.	2.5	22
36	Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial. <i>Cardiology Journal</i> , 2021, , .	0.5	3

#	ARTICLE	IF	CITATIONS
37	Influence of METHoxyflurane on ANtiplatelet Effect of ticagrelor in patients with unstable angina pectoris: Rationale and a protocol of a randomized clinical METHANE-SIRIO 4 study. <i>Cardiology Journal</i> , 2021, , .	0.5	3
38	Inhibitors of sodium-glucose transport protein 2: A new multidirectional therapeutic option for heart failure patients. <i>Cardiology Journal</i> , 2021, , .	0.5	0
39	Assessment of Selected Baseline and Post-PCI Electrocardiographic Parameters as Predictors of Left Ventricular Systolic Dysfunction after a First ST-Segment Elevation Myocardial Infarction. <i>Journal of Clinical Medicine</i> , 2021, 10, 5445.	1.0	6
40	Aspirin as an Adjunctive Pharmacologic Therapy Option for COVID-19: Anti-Inflammatory, Antithrombotic, and Antiviral Effects All in One Agent. <i>Journal of Experimental Pharmacology</i> , 2021, Volume 13, 957-970.	1.5	11
41	Diurnal variations in tissue factor and tissue factor pathway inhibitor concentrations in relation to on-treatment platelet reactivity: an analysis of patients with acute myocardial infarction. <i>Platelets</i> , 2020, 31, 877-883.	1.1	3
42	State of the Art. <i>Cardiology Clinics</i> , 2020, 38, 563-573.	0.9	24
43	von Willebrand Factor Predicts Mortality in ACS Patients Treated with Potent P2Y12 Antagonists and is Inhibited by Aptamer BT200 Ex Vivo. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1282-1290.	1.8	9
44	Long-Term Outcomes Following Coronary Revascularizations in Diabetes Mellitus. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2208-2211.	1.2	2
45	Protocol for a phase 2, randomized, double-blind, placebo-controlled, safety and efficacy study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction study protocol for a randomized controlled trial. <i>Trials</i> , 2020, 21, 744.	0.7	2
46	Comparative Efficacy and Safety of Oral P2Y ₁₂ Inhibitors in Acute Coronary Syndrome. <i>Circulation</i> , 2020, 142, 150-160.	1.6	93
47	Transcatheter Aortic Valve Replacement with Self-Expandable ACURATE neo as Compared to Balloon-Expandable SAPIEN 3 in Patients with Severe Aortic Stenosis: Meta-Analysis of Randomized and Propensity-Matched Studies. <i>Journal of Clinical Medicine</i> , 2020, 9, 397.	1.0	6
48	Impact of Preadmission Morphine on Reinfarction in Patients With ST-Elevation Myocardial Infarction Treated With Percutaneous Coronary Intervention: A Meta-Analysis. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 54-62.	2.3	11
49	Enhanced Inflammation is a Marker for Risk of Post-Infarct Ventricular Dysfunction and Heart Failure. <i>International Journal of Molecular Sciences</i> , 2020, 21, 807.	1.8	28
50	Transcatheter aortic valve replacement with Lotus and Sapien 3 prosthetic valves: a systematic review and meta-analysis. <i>Journal of Thoracic Disease</i> , 2020, 12, 893-906.	0.6	7
51	Levosimendan in the treatment of patients with acute cardiac conditions: an expert opinion of the Association of Intensive Cardiac Care of the Polish Cardiac Society. <i>Kardiologia Polska</i> , 2020, 78, 825-834.	0.3	7
52	Influence of QRS duration and axis on response to cardiac resynchronization therapy in chronic heart failure with reduced left ventricular ejection fraction: A single center study including patients with left bundle branch block. <i>Cardiology Journal</i> , 2020, 27, 575-582.	0.5	3
53	Impact of mild therapeutic hypothermia on bioavailability of ticagrelor in patients with acute myocardial infarction after out-of-hospital cardiac arrest. <i>Cardiology Journal</i> , 2020, 27, 780-788.	0.5	8
54	Ion channel inhibition against COVID-19: A novel target for clinical investigation. <i>Cardiology Journal</i> , 2020, 27, 421-424.	0.5	12

#	ARTICLE	IF	CITATIONS
55	Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines. <i>Cardiology Journal</i> , 2020, 27, 661-676.	0.5	7
56	Creative scientific dispute – different points of view on the protocol and execution of the ISAR-REACT 5 trial. <i>Medical Research Journal</i> , 2020, 5, 41-45.	0.1	0
57	Comparison of temperature measurements in esophagus and urinary bladder in comatose patients after cardiac arrest undergoing mild therapeutic hypothermia. <i>Cardiology Journal</i> , 2020, 27, 735-741.	0.5	6
58	The rationale for Multilevel Educational and Motivational Intervention in Patients after Myocardial Infarction (MEDMOTION) project is to support multicentre randomized clinical trial Evaluating Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndrome (ELECTRA – SIRIO 2). <i>Medical Research Journal</i> , 2020, 5, 244-249.	0.1	1
59	Medical emergency team interventions in patients with ST-segment elevation myocardial infarction in Poland in 2018. <i>Kardiologia Polska</i> , 2020, 78, 292-299.	0.3	3
60	Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines. <i>Medical Research Journal</i> , 2020, 5, 177-190.	0.1	0
61	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 618-628.	5.5	207
62	Short-Term Therapies for Treatment of Acute and Advanced Heart Failure – Why so Few Drugs Available in Clinical Use, Why Even Fewer in the Pipeline?. <i>Journal of Clinical Medicine</i> , 2019, 8, 1834.	1.0	14
63	Platelet inhibition with standard vs. lower maintenance dose of ticagrelor early after myocardial infarction (ELECTRA): a randomized, open-label, active-controlled pharmacodynamic and pharmacokinetic study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 139-148.	1.4	18
64	Risk of Statin-Induced Hypertransaminasemia. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2019, 3, 131-140.	1.2	5
65	Age-Related 2-Year Mortality After Transcatheter Aortic Valve Replacement: the YOUNG TAVR Registry. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1457-1466.	1.4	19
66	Determinants of high platelet reactivity in patients with acute coronary syndromes treated with ticagrelor. <i>Scientific Reports</i> , 2019, 9, 3924.	1.6	16
67	Stratified Approaches to Antiplatelet Therapies Based on Platelet Reactivity Testing. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 176.	1.1	17
68	Transcatheter aortic valve implantation with the new repositionable self-expandable Medtronic Evolut R vs. CoreValve system. <i>Journal of Cardiovascular Medicine</i> , 2019, 20, 226-236.	0.6	9
69	A study of biological and lifestyle factors, including within-subject variation, affecting concentrations of growth differentiation factor 15 in serum. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1035-1043.	1.4	13
70	Safety and efficacy of self-expanding Stentys drug-eluting stent in left main coronary artery PCI: Multicentre LM-SESTENTYS registry. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 574-582.	0.7	3
71	Baseline low-density lipoprotein cholesterol to predict the extent of cardiovascular benefit from lipid-lowering therapies: a review. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 47-54.	1.4	16
72	Bivalirudin use in acute coronary syndrome patients undergoing percutaneous coronary interventions in Poland: Clinical update from expert group of the Association on Cardiovascular Interventions of the Polish Cardiac Society. <i>Cardiology Journal</i> , 2019, 26, 1-7.	0.5	5

#	ARTICLE	IF	CITATIONS
73	75-year-old man with lung cancer obscured by an implantable cardioverter-defibrillator " case report. Medical Research Journal, 2019, 4, 63-66.	0.1	0
74	ISAR-REACT 5 " What have we learned?. Cardiology Journal, 2019, 26, 427-428.	0.5	5
75	Plasma midregional proadrenomedullin (MR-proADM) concentrations and their biological determinants in a reference population. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1161-1168.	1.4	23
76	Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering. JAMA - Journal of the American Medical Association, 2018, 319, 1566.	3.8	339
77	Comparative performance of transcatheter aortic valve-in-valve implantation versus conventional surgical redo aortic valve replacement in patients with degenerated aortic valve bioprostheses: systematic review and meta-analysis. European Journal of Cardio-thoracic Surgery, 2018, 53, 495-504.	0.6	50
78	Perioperative aspirin therapy in non-cardiac surgery: A systematic review and meta-analysis of randomized controlled trials. International Journal of Cardiology, 2018, 258, 59-67.	0.8	14
79	Morphine Interaction with Aspirin: a Double-Blind, Crossover Trial in Healthy Volunteers. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 430-436.	1.3	8
80	Rationale and Design of the Effectiveness of LowEr maintenancE dose of TicagRelor early After myocardial infarction (ELECTRA) pilot study. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 152-157.	1.4	16
81	MEtOclopamide Administration as a Strategy to Overcome MORPHine-ticagrelOr Interaction in PatientS with Unstable Angina PectoriS" The METAMORPHOSIS Trial. Thrombosis and Haemostasis, 2018, 118, 2126-2133.	1.8	39
82	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. New England Journal of Medicine, 2018, 379, 2097-2107.	13.9	2,211
83	Dual vs single antiplatelet therapy in patients with lower extremity peripheral artery disease " A meta-analysis. International Journal of Cardiology, 2018, 269, 292-297.	0.8	14
84	Role of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with coronary artery disease undergoing percutaneous coronary intervention. Expert Review of Cardiovascular Therapy, 2018, 16, 419-429.	0.6	7
85	Evaluating current and emerging antithrombotic therapy currently available for the treatment of acute coronary syndrome in geriatric populations. Expert Opinion on Pharmacotherapy, 2018, 19, 1415-1425.	0.9	9
86	Cangrelor for the treatment of patients with Arterial Thrombosis. Expert Opinion on Pharmacotherapy, 2018, 19, 1389-1398.	0.9	5
87	Metabolism of ticagrelor in patients with acute coronary syndromes. Scientific Reports, 2018, 8, 11746.	1.6	17
88	Treatment of patients with acute coronary syndrome: Recommendations for medical emergency teams: Focus on antiplatelet therapies. Updated experts" standpoint. Cardiology Journal, 2018, 25, 291-300.	0.5	18
89	Carvedilol " is it still the primus inter pares among b-blockers?. Medical Research Journal, 2018, 3, 165-174.	0.1	0
90	High-sensitivity cardiac troponin assays: From improved analytical performance to enhanced risk stratification. Critical Reviews in Clinical Laboratory Sciences, 2017, 54, 143-172.	2.7	51

#	ARTICLE	IF	CITATIONS
91	Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients (PINPOINT): protocol for a prospective, observational, single-centre study. <i>BMJ Open</i> , 2017, 7, e013218.	0.8	8
92	Repetitive use of levosimendan in advanced heart failure: need for stronger evidence in a field in dire need of a useful therapy. <i>International Journal of Cardiology</i> , 2017, 243, 389-395.	0.8	26
93	Establishing reference intervals for galectin-3 concentrations in serum requires careful consideration of its biological determinants. <i>Clinical Biochemistry</i> , 2017, 50, 599-604.	0.8	14
94	Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 376, 1713-1722.	13.9	4,179
95	Impact of levosimendan on platelet function. <i>Thrombosis Research</i> , 2017, 159, 76-81.	0.8	5
96	Implantable Cardioverter-Defibrillators for Primary Prevention in Patients With Ischemic or Nonischemic Cardiomyopathy. <i>Annals of Internal Medicine</i> , 2017, 167, 103.	2.0	43
97	Prasugrel in critically ill patients. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1582-1587.	1.8	13
98	Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-a systematic review and network meta-analysis. <i>PLoS ONE</i> , 2017, 12, e0168726.	1.1	25
99	The impact of the time of drug administration on the effectiveness of combined treatment of hypercholesterolemia with Rosuvastatin and Ezetimibe (RosEze): study protocol for a randomized controlled trial. <i>Trials</i> , 2017, 18, 316.	0.7	4
100	Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina. <i>Thrombosis and Haemostasis</i> , 2017, 117, 718-726.	1.8	30
101	High-risk percutaneous coronary intervention with Impella CP hemodynamic support. A case series and method presentation. <i>Postępy W Kardiologii Interwencyjnej</i> , 2017, 1, 67-71.	0.1	1
102	Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study. <i>PLoS ONE</i> , 2017, 12, e0186013.	1.1	19
103	Anti-aggregation therapy in patients with acute coronary syndrome " recommendations for medical emergency teams. Experts™ standpoint. <i>Kardiologia Polska</i> , 2017, 75, 399-408.	0.3	5
104	Platelet reactivity during mild therapeutic hypothermia in patients with acute myocardial infarction treated with ticagrelor: study protocol of a single-centre study. <i>Medical Research Journal</i> , 2017, 1, 115-119.	0.1	0
105	Anti-aggregation therapy in patients with acute coronary syndrome " recommendations for medical emergency teams. Experts™ standpoint. <i>Kardiologia Polska</i> , 2017, 75, 47-56.	0.3	0
106	Znaczenie kliniczne interakcji morfina " doustni antagoniści pÅytkowego receptora P2Y12 u chorych z ostrym zespoÅem wieÅcowym " komentarz do artykuÅu. <i>Kardiologia Polska</i> , 2017, 75, 58-59.	0.3	0
107	Circulatory support with Impella CP device during high-risk percutaneous coronary interventions: initial experience in Poland. <i>Postępy W Kardiologii Interwencyjnej</i> , 2016, 3, 254-257.	0.1	6
108	Effect of chokeberry juice consumption on antioxidant capacity, lipids profile and endothelial function in healthy people: a pilot study. <i>Czech Journal of Food Sciences</i> , 2016, 34, 39-46.	0.6	16

#	ARTICLE	IF	CITATIONS
109	Which platelet function test best reflects the in vivo plasma concentrations of ticagrelor and its active metabolite?. <i>Thrombosis and Haemostasis</i> , 2016, 116, 1140-1149.	1.8	10
110	State of the art: Oral antiplatelet therapy. <i>JRSM Cardiovascular Disease</i> , 2016, 5, 204800401665251.	0.4	6
111	Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors. <i>International Journal of Cardiology</i> , 2016, 215, 201-208.	0.8	61
112	Adherence to antiplatelet treatment with P2Y12 receptor inhibitors. Is there anything we can do to improve it? A systematic review of randomized trials. <i>Current Medical Research and Opinion</i> , 2016, 32, 1441-1451.	0.9	19
113	Abciximab as a bridging strategy to overcome morphine's prasugrel interaction in STEMI patients. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1343-1350.	1.1	30
114	New directions for pharmacotherapy in the treatment of acute coronary syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2291-2306.	0.9	15
115	Impact of lipid markers and high-sensitivity C-reactive protein on the value of the 99th percentile upper reference limit for high-sensitivity cardiac troponin I. <i>Clinica Chimica Acta</i> , 2016, 462, 193-200.	0.5	7
116	Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 1361-1370.	0.6	3
117	Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. <i>European Heart Journal</i> , 2016, 37, 245-252.	1.0	217
118	Morphine decreases ticagrelor concentrations but not its antiplatelet effects: a randomized trial in healthy volunteers. <i>European Journal of Clinical Investigation</i> , 2016, 46, 7-14.	1.7	56
119	Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. <i>Journal of the American Heart Association</i> , 2016, 5, e002197.	1.6	127
120	Admission glucose and left ventricular systolic function in non-diabetic patients with acute myocardial infarction. <i>Heart and Vessels</i> , 2016, 31, 298-307.	0.5	5
121	Prediction of high risk of non-adherence to antiplatelet treatment. <i>Kardiologia Polska</i> , 2016, 74, 61-67.	0.3	14
122	Impact of ticagrelor administration strategy on its pharmacokinetics and pharmacodynamics in patients with unstable angina pectoris: a protocol of a randomized study. <i>Medical Research Journal</i> , 2016, 1, 10-14.	0.1	3
123	Percutaneous left atrial appendage closure for thromboembolic prophylaxis in patients with atrial fibrillation. The impact of operator's experience on the procedure course. <i>Medical Research Journal</i> , 2016, 3, 160-164.	0.1	1
124	Diabetogenic effect of statins: a comprehensive review on the clinical relevance, underlying pathomechanisms and rationale for tailored statin therapy. <i>Medical Research Journal</i> , 2016, 3, 145-153.	0.1	3
125	Successful reduction of severe mitral regurgitation after implantation of four MitraClip devices. <i>Medical Research Journal</i> , 2016, 3, 176-179.	0.1	0
126	Impact of prior statin therapy on evaluation of the inflammatory process and cortisol concentration in patients with the first ST-segment elevation myocardial infarction undergoing coronary angioplasty with bare metal stent implantation. <i>Medical Research Journal</i> , 2016, 1, 28-36.	0.1	0

#	ARTICLE	IF	CITATIONS
127	Device-associated thrombus after percutaneous left atrial appendage closure: a case report and literature review. <i>Medical Research Journal</i> , 2016, 1, 48-52.	0.1	1
128	Mild therapeutic hypothermia for patients with acute coronary syndrome and cardiac arrest treated with percutaneous coronary intervention (UNICORN). The design and rationale for the prospective, observational, multicenter study. <i>Medical Research Journal</i> , 2016, 1, 23-27.	0.1	0
129	The influence of metoclopramide on pharmacokinetics and pharmacodynamics of ticagrelor in patients with unstable angina pectoris receiving concomitant treatment with morphine – a protocol of a randomized trial. <i>Medical Research Journal</i> , 2016, 1, 68-71.	0.1	1
130	Personalized antiplatelet therapy with P2Y ₁₂ receptor inhibitors: benefits and pitfalls. <i>Postępy W Kardiologii Interwencyjnej</i> , 2015, 4, 259-280.	0.1	23
131	Use of time-resolved fluorescence spectroscopy to evaluate diagnostic value of collagen degradation products. <i>Journal of Biomedical Optics</i> , 2015, 20, 051039.	1.4	5
132	Acetylsalicylic acid resistance risk factors in patients with myocardial infarction. <i>Pharmacological Reports</i> , 2015, 67, 952-958.	1.5	9
133	Efficacy of clostrazol on inhibition of platelet aggregation, inflammation and myonecrosis in acute coronary syndrome patients undergoing percutaneous coronary intervention: The ACCEL-LOADING-ACS (ACCErated Inhibition of Platelet Aggregation, Inflammation and Myonecrosis by) Tj ETQq1o1s0.784314 rgBT <i>Journal of Cardiology</i> , 2015, 100, 270-275.	1.4	14
134	Complete revascularisation in ST-elevation myocardial infarction and multivessel disease: meta-analysis of randomised controlled trials. <i>Heart</i> , 2015, 101, 1309-1317.	1.2	40
135	Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia. <i>Annals of Internal Medicine</i> , 2015, 163, 40-51.	2.0	357
136	Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Acute Myocardial Infarction (IMPRESSION): study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 198.	0.7	15
137	Discrepancies in Assessment of Adherence to Antiplatelet Treatment after Myocardial Infarction. <i>Pharmacology</i> , 2015, 95, 50-58.	0.9	24
138	Comprehensive Meta-Analysis of Safety and Efficacy of Bivalirudin Versus Heparin With or Without Routine Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Coronary Syndrome. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 201-213.	1.1	69
139	The number of circulating endothelial progenitor cells in healthy individuals – Effect of some anthropometric and environmental factors (a pilot study). <i>Advances in Medical Sciences</i> , 2015, 60, 58-63.	0.9	9
140	A novel multiplex assay amplifying 13 Y-STRs characterized by rapid and moderate mutation rate. <i>Forensic Science International: Genetics</i> , 2015, 15, 49-55.	1.6	19
141	Associations between selected angiographic parameters and the number of CD34+ cells and plasma levels of vascular endothelial growth factor and angiogenin in patients with ST-segment elevation myocardial infarction. <i>Polish Archives of Internal Medicine</i> , 2015, 125, 132-140.	0.3	3
142	Genetyczne aspekty farmakokinetyki i farmakodynamiki kłopidogrelu. <i>Folia Cardiologica</i> , 2015, 10, 275-282.	0.1	0
143	Does morphine administration affect ticagrelor conversion to its active metabolite in patients with acute myocardial infarction? A sub-analysis of the randomized, double-blind, placebo- -controlled IMPRESSION trial. <i>Medical Research Journal</i> , 2015, 3, 100-106.	0.1	0
144	A systematic review on the role of bivalirudin in patients undergoing percutaneous coronary interventions: primus inter pares or a falling star?. <i>Medical Research Journal</i> , 2015, 3, 79-88.	0.1	0

#	ARTICLE	IF	CITATIONS
145	Variability of prasugrel antiplatelet effect in patients with acute coronary syndrome. <i>Medical Research Journal</i> , 2015, 3, 117-124.	0.1	0
146	ARCHITECT STAT High Sensitive Troponin I Familiarization Study (FAM) in the Department of Laboratory Medicine, Collegium Medicum, Nicolaus Copernicus University in Bydgoszcz, Poland. <i>Medical Research Journal</i> , 2015, 3, 107-112.	0.1	0
147	Interplay between Genetic and Clinical Variables Affecting Platelet Reactivity and Cardiac Adverse Events in Patients Undergoing Percutaneous Coronary Intervention. <i>PLoS ONE</i> , 2014, 9, e102701.	1.1	23
148	Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors. <i>Thrombosis and Haemostasis</i> , 2014, 112, 224-242.	1.8	41
149	Cangrelor: an emerging therapeutic option for patients with coronary artery disease. <i>Current Medical Research and Opinion</i> , 2014, 30, 813-828.	0.9	28
150	Statins and Risk of New-Onset Diabetes Mellitus: is there a Rationale for Individualized Statin Therapy?. <i>American Journal of Cardiovascular Drugs</i> , 2014, 14, 79-87.	1.0	29
151	Meta-Analysis of Time-Related Benefits of Statin Therapy in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2014, 113, 1753-1764.	0.7	80
152	First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients. <i>Open Heart</i> , 2014, 1, e000064.	0.9	88
153	Time-related changes in determinants of antiplatelet effect of clopidogrel in patients after myocardial infarction. <i>European Journal of Pharmacology</i> , 2014, 742, 47-54.	1.7	30
154	Clinical significance of <i>Helicobacter pylori</i> infection in patients with acute coronary syndromes: an overview of current evidence. <i>Clinical Research in Cardiology</i> , 2014, 103, 855-886.	1.5	19
155	Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: The Randomized Double-Blind Reminder Study. <i>European Heart Journal</i> , 2014, 35, 2295-2302.	1.0	128
156	Short and long-term safety and efficacy of polymer-free vs. durable polymer drug-eluting stents. A comprehensive meta-analysis of randomized trials including 6178 patients. <i>Atherosclerosis</i> , 2014, 233, 224-231.	0.4	25
157	Critical appraisal of inflammatory markers in cardiovascular risk stratification. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2014, 51, 263-279.	2.7	67
158	Off-target effects of glycoprotein IIb/IIIa receptor inhibitors. <i>Cardiology Journal</i> , 2014, 21, 458-464.	0.5	14
159	Prasugrel overcomes high on-clopidogrel platelet reactivity in the acute phase of acute coronary syndrome and maintains its antiplatelet potency at 30-day follow-up. <i>Cardiology Journal</i> , 2014, 21, 547-556.	0.5	20
160	Influence of cardiac resynchronization therapy on oxidative stress markers in patients with chronic heart failure. <i>Cardiology Journal</i> , 2014, 21, 576-582.	0.5	4
161	Optimal Timing of Coronary Invasive Strategy in Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Annals of Internal Medicine</i> , 2013, 158, 261.	2.0	151
162	Drug-coated balloons in treatment of in-stent restenosis: a meta-analysis of randomised controlled trials. <i>Clinical Research in Cardiology</i> , 2013, 102, 279-287.	1.5	29

#	ARTICLE	IF	CITATIONS
163	Low-dose of oral factor Xa inhibitors in patients with a recent acute coronary syndrome: A systematic review and meta-analysis of randomized trials. <i>Atherosclerosis</i> , 2013, 229, 482-488.	0.4	7
164	A critical overview on ticagrelor in acute coronary syndromes. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2013, 106, 105-115.	0.2	16
165	Neither Cyclosporine nor Tacrolimus Deteriorate Endothelial Function in Renal Transplant Recipients Assessed With Reactive Hyperemia Index. <i>Transplantation Proceedings</i> , 2013, 45, 1567-1570.	0.3	3
166	Meta-Analysis of Impact of Different Types and Doses of Statins on New-Onset Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2013, 111, 1123-1130.	0.7	239
167	Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 447-462.	0.6	18
168	ACS network-based implementation of therapeutic hypothermia for the treatment of comatose out-of-hospital cardiac arrest survivors improves clinical outcomes: the first European experience. <i>Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine</i> , 2013, 21, 22.	1.1	17
169	High-Dose, but Not Low-Dose, Aspirin Impairs Anticontractile Effect of Ticagrelor following ADP Stimulation in Rat Tail Artery Smooth Muscle Cells. <i>BioMed Research International</i> , 2013, 2013, 1-8.	0.9	14
170	Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. <i>BMJ, The</i> , 2013, 347, f6530-f6530.	3.0	194
171	Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent. <i>EuroIntervention</i> , 2013, 9, 308-315.	1.4	38
172	Does mobilisation of CD34+ stem cells along with VEGF, angiogenin, IL-6, IL-8, and hsCRP levels allow predicting the direction of left ventricular ejection fraction and wall motion score index changes in patients with myocardial infarction?. <i>Kardiologia Polska</i> , 2013, 71, 464-471.	0.3	4
173	Manual vs mechanical thrombectomy during PCI for STEMI: a comprehensive direct and adjusted indirect meta-analysis of randomized trials. <i>American Journal of Cardiovascular Disease</i> , 2013, 3, 146-57.	0.5	9
174	Value of C-Reactive Protein in Predicting Left Ventricular Remodelling in Patients with a First ST-Segment Elevation Myocardial Infarction. <i>Mediators of Inflammation</i> , 2012, 2012, 1-11.	1.4	29
175	Value of C-Reactive Protein as a Risk Factor for Acute Coronary Syndrome: A Comparison with Apolipoprotein Concentrations and Lipid Profile. <i>Mediators of Inflammation</i> , 2012, 2012, 1-10.	1.4	19
176	Adenosine improves post-procedural coronary flow but not clinical outcomes in patients with acute coronary syndrome: A meta-analysis of randomized trials. <i>Atherosclerosis</i> , 2012, 222, 1-7.	0.4	36
177	Clinical efficacy and safety of intracoronary vs. intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention: A meta-analysis of randomized trials. <i>Platelets</i> , 2012, 23, 274-281.	1.1	29
178	Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: A placebo-controlled study in rats. <i>Thrombosis Research</i> , 2012, 130, 65-69.	0.8	42
179	Ticagrelor in the treatment of coronary artery disease patients. <i>Clinical Practice (London, England)</i> , 2012, 9, 373-390.	0.1	0
180	Caution in interpreting the findings from small observational studies. <i>International Journal of Cardiology</i> , 2012, 160, 71.	0.8	0

#	ARTICLE	IF	CITATIONS
181	Twelve-month results of a Paclitaxel Releasing Balloon in Patients Presenting with In-stent Restenosis First-in-Man (PEPPER) trial. <i>Cardiovascular Revascularization Medicine</i> , 2012, 13, 260-264.	0.3	35
182	Endothelial cell markers in coronary artery disease. <i>Postepy W Kardiologii Interwencyjnej</i> , 2012, 4, 275-279.	0.1	0
183	Usefulness of C-reactive protein as a marker of early post-infarct left ventricular systolic dysfunction. <i>Inflammation Research</i> , 2012, 61, 725-734.	1.6	20
184	Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUSâ€PCI study. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 529-542.	1.9	81
185	Stress hyperglycaemia in patients with first myocardial infarction. <i>International Journal of Clinical Practice</i> , 2012, 66, 592-601.	0.8	17
186	Updated evidence on intracoronary abciximab in ST-elevation myocardial infarction: A systematic review and meta-analysis of randomized clinical trials. <i>Cardiology Journal</i> , 2012, 19, 230-242.	0.5	13
187	Occurrence and predictors of left ventricular systolic dysfunction at hospital discharge and in long-term follow-up after acute myocardial infarction treated with primary percutaneous coronary intervention. <i>Kardiologia Polska</i> , 2012, 70, 329-40.	0.3	6
188	Intracoronary versus intravenous abciximab administration in STEMI patients: overview of current status and open questions. <i>Current Medical Research and Opinion</i> , 2011, 27, 2133-2144.	0.9	11
189	Efficacy and Safety of Celivarone, With Amiodarone as Calibrator, in Patients With an Implantable Cardioverter-Defibrillator for Prevention of Implantable Cardioverter-Defibrillator Interventions or Death. <i>Circulation</i> , 2011, 124, 2649-2660.	1.6	45
190	Early vs. delayed invasive strategy in patients with acute coronary syndromes without ST-segment elevation: a meta-analysis of randomized studies. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2011, 104, 193-200.	0.2	39
191	Diurnal variation in platelet inhibition by clopidogrel. <i>Platelets</i> , 2011, 22, 579-587.	1.1	52
192	"Sirolimus or paclitaxel drug eluting stent in left main disease: The winner isâ€". <i>International Journal of Cardiology</i> , 2011, 152, 387.	0.8	2
193	Diagnostic efficacy of myeloperoxidase for the detection of acute coronary syndromes. <i>European Journal of Clinical Investigation</i> , 2011, 41, 667-671.	1.7	23
194	Lowâ€molecularâ€weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for STâ€elevation myocardial infarction: a metaâ€analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1902-1915.	1.9	68
195	Value of oral glucose tolerance test in the acute phase of myocardial infarction. <i>Cardiovascular Diabetology</i> , 2011, 10, 21.	2.7	11
196	Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2011, 104, 561-569.	0.2	34
197	How Do Apolipoproteins ApoB and ApoA-I Perform in Patients with Acute Coronary Syndromes. <i>Journal of Medical Biochemistry</i> , 2011, 30, 237-243.	0.7	13
198	Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. <i>Heart</i> , 2011, 97, 98-105.	1.2	64

#	ARTICLE	IF	CITATIONS
199	Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials. <i>EuroIntervention</i> , 2011, 7, 985-994.	1.4	87
200	Reliability of heart rate variability measurements in patients with a history of myocardial infarction. <i>Clinical Science</i> , 2010, 118, 195-201.	1.8	29
201	Impact of diabetes on survival in patients with ST-segment elevation myocardial infarction treated by primary angioplasty: Insights from the POLISH STEMI registry. <i>Atherosclerosis</i> , 2010, 210, 516-520.	0.4	37
202	Influence of different antiplatelet treatment regimens for primary percutaneous coronary intervention on all-cause mortality. <i>European Heart Journal</i> , 2009, 30, 1736-1743.	1.0	15
203	The Use of Biochip Cardiac Array Technology for Early Diagnosis of Acute Coronary Syndromes. <i>Journal of Medical Biochemistry</i> , 2009, 28, 293-299.	0.7	9
204	Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome. <i>Cardiology Journal</i> , 2009, 16, 535-44.	0.5	24
205	Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2008, 372, 807-816.	6.3	934
206	Detection of Cardiac-Related Diseases Using Nonlinear Analysis of Short-Term ECG Signal with Aural Stimuli. , 2008, , .		0
207	The BEAUTIFUL Study: Randomized Trial of Ivabradine in Patients with Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction – Baseline Characteristics of the Study Population. <i>Cardiology</i> , 2008, 110, 271-282.	0.6	39
208	Gender differences and in-hospital mortality in patients undergoing percutaneous coronary interventions. <i>Kardiologia Polska</i> , 2008, 66, 632-9; discussion 640-1.	0.3	6
209	No-reflow phenomenon: Achilles' heel of primary coronary angioplasty in acute myocardial infarction. <i>Cardiology Journal</i> , 2008, 15, 1-3.	0.5	20
210	The reliability of noninvasive cardiac output measurement using the inert gas rebreathing method in patients with advanced heart failure. <i>Cardiology Journal</i> , 2008, 15, 63-70.	0.5	18
211	Immunoglobulin E in patients with ischemic heart disease. <i>Cardiology Journal</i> , 2008, 15, 122-8.	0.5	18
212	Predicted and observed in-hospital mortality after left main coronary artery stenting in 204 patients. <i>Cardiology Journal</i> , 2008, 15, 268-76.	0.5	4
213	The effect of trimetazidine added to maximal anti-ischemic therapy in patients with advanced coronary artery disease. <i>Cardiology Journal</i> , 2008, 15, 344-50.	0.5	11
214	Increased morning ADP-dependent platelet aggregation persists despite dual antiplatelet therapy in patients with first ST-segment elevation myocardial infarction: Preliminary report. <i>Cardiology Journal</i> , 2008, 15, 530-6.	0.5	7
215	Usefulness of optical coherence tomography in the assessment of atherosclerotic culprit lesions in acute coronary syndromes. Comparison with intravascular ultrasound and virtual histology. <i>Cardiology Journal</i> , 2008, 15, 561-3.	0.5	3
216	Periprocedural soluble P- and E-selectin levels fail as predictors of clinical restenosis in patients treated with elective coronary stenting. <i>International Journal of Molecular Medicine</i> , 2007, 19, 187.	1.8	1

#	ARTICLE	IF	CITATIONS
217	Comparison of angiographically guided direct stenting technique with direct stenting and optimal balloon angioplasty guided with intravascular ultrasound. The multicenter, randomized trial results. <i>American Heart Journal</i> , 2007, 154, 669-675.	1.2	41
218	One-year outcomes of left main coronary artery stenting in patients with cardiogenic shock. <i>Cardiology Journal</i> , 2007, 14, 67-75.	0.5	7
219	Percutaneous coronary angioplasty in elderly patients: Assessment of in-hospital outcomes. <i>Cardiology Journal</i> , 2007, 14, 143-54.	0.5	3
220	Immunoglobulin E as a marker of the atherothrombotic process in patients with acute myocardial infarction. <i>Cardiology Journal</i> , 2007, 14, 266-73.	0.5	5
221	Thrombolysis in cardiac arrest: Initial enthusiasm tempered. <i>Cardiology Journal</i> , 2007, 14, 422-3.	0.5	0
222	Smokers versus non-smokers undergoing percutaneous transluminal coronary angioplasty: The impact of clinical and procedural characteristics on in-hospital mortality. <i>Cardiology Journal</i> , 2007, 14, 482-92.	0.5	7
223	Endothelial function parameters in patients with unstable angina and infection with <i>Helicobacter pylori</i> and <i>Chlamydia pneumoniae</i> . <i>European Journal of Internal Medicine</i> , 2006, 17, 339-342.	1.0	15
224	Percutaneous coronary intervention triggers a systemic inflammatory response in patients treated for in-stent restenosis – comparison with stable and unstable angina. <i>Inflammation Research</i> , 2005, 54, 187-193.	1.6	28
225	Combined periprocedural evaluation of CRP and TNF-alpha enhances the prediction of clinical restenosis and major adverse cardiac events in patients undergoing percutaneous coronary interventions. <i>International Journal of Molecular Medicine</i> , 2005, 16, 173-80.	1.8	21
226	Threshold parameters of left main coronary artery stem stenosis based on intracoronary ultrasound examination. <i>Kardiologia Polska</i> , 2005, 63, 223-31; discussion 232-3.	0.3	9
227	Myocardial infarction with normal coronary arteriogram: the role of ephedrine-like alkaloids. <i>Medical Science Monitor</i> , 2004, 10, CS15-21.	0.5	11
228	Left ventricle systolic volume in vasovagal syncope patients. <i>Folia Morphologica</i> , 2003, 62, 175-8.	0.4	3
229	Analysis of the relationship between the inner structure and the magnitude of atherosclerotic plaques. <i>Folia Morphologica</i> , 2003, 62, 369-75.	0.4	0
230	Antibodies to <i>Chlamydia pneumoniae</i> and haemostatic factors in acute coronary syndrome without ST segment elevation. <i>Kardiologia Polska</i> , 2002, 57, 297-305.	0.3	1
231	Endothelial dysfunction in acute coronary syndrome without ST segment elevation in the presence of <i>Helicobacter pylori</i> infection. <i>Kardiologia Polska</i> , 2002, 57, 533-4; discussion 541.	0.3	2
232	Correlation between clinical and morphologic findings in unstable angina. <i>American Journal of Cardiology</i> , 1996, 77, 128-132.	0.7	20
233	Influence of plaque composition on luminal gain after balloon angioplasty, directional atherectomy, and coronary stenting. <i>American Heart Journal</i> , 1995, 130, 971-975.	1.2	11
234	Effects of coronary angioplasty on left ventricular function. <i>American Journal of Cardiology</i> , 1993, 72, G119-G123.	0.7	4

#	ARTICLE	IF	CITATIONS
235	Assessment of left ventricular function by isometric handgrip exercise after thrombolysis in patients with refractory unstable angina. American Journal of Cardiology, 1993, 72, G140-G144.	0.7	0
236	Influence of elastic recoil on restenosis after successful coronary angioplasty in unstable angina pectoris. American Journal of Cardiology, 1993, 71, 659-663.	0.7	19
237	Atrioventricular Conduction Disturbances in Patients with Sinoatrial Node Disease and Atrial Pacing. PACE - Pacing and Clinical Electrophysiology, 1992, 15, 2074-2076.	0.5	10
238	Left Atrial Size and Wall Motion in Patients with Permanent Ventricular and Atrial Pacing. PACE - Pacing and Clinical Electrophysiology, 1990, 13, 1737-1741.	0.5	15
239	Transesophageal Atrial Pacing Complications in Patients Suspected of Tachy-Brady Syndrome. PACE - Pacing and Clinical Electrophysiology, 1990, 13, 2048-2053.	0.5	3
240	Transesophageal Programmed Atrial Pacing as a Method of Selecting Patients with Sick Sinus Syndrome for Permanent Atrial Pacing. PACE - Pacing and Clinical Electrophysiology, 1988, 11, 1655-1661.	0.5	3
241	The influence of naloxone on pharmacokinetics and pharmacodynamics of ticagrelor in patients with unstable angina pectoris receiving concomitant treatment with morphine – a protocol of a randomized trial. Medical Research Journal, 0, , .	0.1	0
242	Rationale and design of PREvalence of Dyspnea in patients treated with TicagrelOR (PREDATOR) program. Medical Research Journal, 0, , .	0.1	0